DRMA Dermata Corp: Rasio rega marang prakiraan pendapatan

Automated formula screening and AI skin modeling minimize routine tasks, impacting the projected P/S of Dermata Therapeutics (DRMA), where the 46.70 metric determines this level. Physician confidence in non-steroidal treatments strengthens the brand image. Anticipation of final test results for rosacea drugs will act as a growth catalyst, as current R&D expenditures are already priced into the asset value.

DRMA dermatarx.com: Multiplikator forward rega marang pendapatan ing interval 12.11.2026 - 13.11.2026

Rincian analitis perusahaan Dermata Corp (DRMA)

- rega saiki lan proyeksi nilai saham:

Rega saham Dermata Therapeutics, Inc.|DRMA - Rata-rata rega prakiraan

- data kapitalisasi saham perusahaan:

Nilai pasar Dermata Corp|DRMA - Nilai Dipunlarasaken Utang lan Kas

- indikator nilai buku ekuitas:

Aset Bersih saben Siji Saham Dermata Therapeutics|DRMA - Aset Bersih Perusahaan|Rasio Kapitalisasi Pasar marang Nilai Buku dermatarx.com|DRMA - Total Aset Perusahaan

- informasi babagan utang lan solvabilitas:

Rasio Total Utang marang Ekuitas Dermata Therapeutics|DRMA - Rasio silihan jangka dawa marang modal|Utang jangka cendhak marang modal Dermata Therapeutics|DRMA - Gunggung utang perusahaan|Utang marang nilai buku Dermata Corp|DRMA - Silihan lan utang jangka dawa perusahaan|Kewajiban jangka cendhak perusahaan Dermata Therapeutics|Rasio cepet dermatarx.com

- data bathi bisnis lan rasio investasi:

DRMA - Bathi pungkasan|Proyeksi bathi mangsa ngarep Dermata Therapeutics|DRMA - Kapitalisasi marang bathi|Rega marang bathi mangsa ngarep Dermata|DRMA - Koefisien bali modal nimbang wutah|Pangali EV/EBITDA Dermata Corp|DRMA - Bathi operasional EBITDA|Bathi saben saham sajrone rolas wulan pungkasan Dermata Therapeutics|DRMA - Bathi saben siji saham sajrone 12 wulan pungkasan|Wutah bathi EPS kuartalan dermatarx.com|DRMA - Kacepetan wutah bathi saben saham ing taun lumaku|Prakiraan wutah bathi saben saham kanggo taun ngarep Dermata Therapeutics

- data dodolan lan asil:

DRMA - Pendapatan lan volume dodolan|Volume dodolan mangsa ngarep perusahaan Dermata Therapeutics, Inc.|DRMA - Kapitalisasi marang volume dodolan|Multiplikator Forward P/S Dermata Corp

Analisis fundamental perusahaan:Dermata Therapeutics, Inc. (DRMA)

Forward P/S is defined as the ratio of the current share price to the expected revenue per share, allowing for the assessment of the company's market value relative to its projected cash flows. The trend of the forward P/S indicator reflects the sensitivity of Dermata Therapeutics (DRMA) capitalization to the success of acne and rosacea therapy development in collaboration with clinics, signaling a revaluation of the potential for innovative substance delivery.

Pesaing wigati

Multiplikator Forward P/S KRYS (Krystal Biotech)|Apogee Therapeutics Inc (APGE) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|ARQT - Rasio rega marang prakiraan pendapatan|Rega forward marang dodolan VCEL (Vericel Inc.)|Oruka Therapeutics Inc (ORKA) - Rasio rega marang prakiraan pendapatan|Multiplikator forward rega marang pendapatan Sanara MedTech|DBVT (DBV Tech) - Multiplikator Forward P/S|Multiplikator Forward P/S Solesence Inc.|Multiplikator forward rega marang pendapatan DERM (Journey Medical)|Rasio rega marang pendapatan sing dikarepake FBRX|Multiplikator Forward P/S EMPG (Empro Group Inc)|Multiplikator Forward P/S sol-gel.com SLGL|AXIL: Multiplikator forward rega marang pendapatan|Rega forward marang dodolan MDCX (Medicus Pharma Ltd)|VRCA (verrica.com) - Multiplikator forward rega marang pendapatan|HOTH: Rasio rega marang pendapatan sing dikarepake|BFRI (Biofrontera, Inc.) - Multiplikator Forward P/S|VYNE: Rega forward marang dodolan|Multiplikator Forward P/S SNOA|QNRX - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Rasio rega marang prakiraan pendapatan Azitra Corp AZTR|Rega forward marang dodolan ELAB|Revance Therapeutics - Multiplikator Forward P/S